Ep. 346 - 2026 Public Markets Preview

January 23, 2026

30 min episode · 2 min read

Steven Hansen,Simone Fishburne,Selena Koch

Episode

30 min

Read time

2 min

AI-Generated Summary

Published Mar 15, 2026

Key Takeaways

✓Recovery Benchmark: The XBI rose 36% in 2024 and 83% from its April trough, outperforming the S&P 500, tech sector, and Magnificent Seven. Investors tracking sector re-entry should use this baseline to assess whether current valuations still represent undervalued entry points relative to four years of underperformance.
✓2012–2013 Analog: Investors who lived through the post-2008 recovery draw a direct parallel to today: then, six mid-cap biotechs (Gilead HCV, Vertex Kalydeco, Regeneron Eylea, Biogen Tecfidera, Amgen Denosumab, Celgene Revlimid) drove a sector-wide IPO wave. Today, at least 23 companies enter 2026 with high-growth commercial launches, distributing risk more broadly.
✓Generalist Capital Signal: On December 9, 2024 alone, $3.3 billion in follow-on offerings closed, all substantially upsized. Mutual funds that previously requested minimum allocations began offering to fund entire deals solo. Investors monitoring sector momentum should track follow-on upsizing rates as a leading indicator of generalist re-entry before IPO windows open.
✓IPO Quality Discipline: Bankers and investors identify a slew of underperforming post-IPO stocks as the single most likely momentum killer for 2026. The strategy: only the highest-quality, late-stage private companies—seasoned through an extended bear market—should price first, with a broader window expected around May–June if early names like Aptis Oncology hold their pricing.
✓FDA Risk Framework: FDA remains the sole major overhang, splitting investors into two camps. One camp notes that most portfolio companies still report normal FDA interactions despite staffing reductions. The other warns that accumulated disruption will compound over time, potentially delaying PDUFA-dated launches and shifting valuation models by one to two years for pipeline-stage assets.

What It Covers

BioCentury's 2026 public markets preview examines why biotech's recovery—marked by XBI returning 36% in 2024 and outperforming the Magnificent Seven—may finally be durable, analyzing 23 commercial-stage companies, generalist capital rotation, sustained M&A activity, and FDA regulatory uncertainty as the primary remaining headwind.

Key Questions Answered

•Recovery Benchmark: The XBI rose 36% in 2024 and 83% from its April trough, outperforming the S&P 500, tech sector, and Magnificent Seven. Investors tracking sector re-entry should use this baseline to assess whether current valuations still represent undervalued entry points relative to four years of underperformance.
•2012–2013 Analog: Investors who lived through the post-2008 recovery draw a direct parallel to today: then, six mid-cap biotechs (Gilead HCV, Vertex Kalydeco, Regeneron Eylea, Biogen Tecfidera, Amgen Denosumab, Celgene Revlimid) drove a sector-wide IPO wave. Today, at least 23 companies enter 2026 with high-growth commercial launches, distributing risk more broadly.
•Generalist Capital Signal: On December 9, 2024 alone, $3.3 billion in follow-on offerings closed, all substantially upsized. Mutual funds that previously requested minimum allocations began offering to fund entire deals solo. Investors monitoring sector momentum should track follow-on upsizing rates as a leading indicator of generalist re-entry before IPO windows open.
•IPO Quality Discipline: Bankers and investors identify a slew of underperforming post-IPO stocks as the single most likely momentum killer for 2026. The strategy: only the highest-quality, late-stage private companies—seasoned through an extended bear market—should price first, with a broader window expected around May–June if early names like Aptis Oncology hold their pricing.
•FDA Risk Framework: FDA remains the sole major overhang, splitting investors into two camps. One camp notes that most portfolio companies still report normal FDA interactions despite staffing reductions. The other warns that accumulated disruption will compound over time, potentially delaying PDUFA-dated launches and shifting valuation models by one to two years for pipeline-stage assets.

Key Topics

The strategy

only the highest-quality, late-stage private companies—seasoned through an extended bear market—should price first, with a broader window expected around May–June if early names like Aptis Oncology hold their pricing.

Notable Moment

A banker described how mutual fund behavior reversed completely within twelve months: funds that once requested only minimum follow-on allocations began offering to purchase entire $150 million deals outright, forcing banks to upsize offerings just to accommodate other investors seeking access to the same positions.

Know someone who'd find this useful?